

# Gianluca Perego

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4459090/gianluca-perego-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19  
papers

104  
citations

4  
h-index

10  
g-index

20  
ext. papers

176  
ext. citations

3.7  
avg, IF

3.02  
L-index

#	Paper	IF	Citations
19	Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. <i>Cancers</i> , <b>2019</b> , 11,	6.6	36
18	Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2021</b> , 211, 105883	5.1	32
17	Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	11
16	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , <b>2020</b> , 35, 783-794	3	5
15	Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. <i>Medical Oncology</i> , <b>2020</b> , 37, 81	3.7	4
14	Association of steroid use with survival in solid tumours. <i>European Journal of Cancer</i> , <b>2020</b> , 141, 105-114	7.5	4
13	Effects of hypertension on cancer survival: A meta-analysis. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , 51, e13493	4.6	4
12	Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug?. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 967-971	1.7	3
11	Continuous-infusion and outpatient setting: A chance for patients, a challenge for hospital pharmacists. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 1715-1720	1.7	2
10	Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 2069-2072	1.7	1
9	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. <i>World Journal of Methodology</i> , <b>2021</b> , 11, 95-109	1.2	1
8	Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility?. <i>Tumori</i> , <b>2021</b> , 3008916211061604	1.7	0
7	Osimertinib-related venous thromboembolism in non small lung cancer.. <i>Thrombosis Research</i> , <b>2021</b> , 210, 63-66	8.2	0
6	Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 720748	8.4	0
5	Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.. <i>Breast Cancer: Targets and Therapy</i> , <b>2022</b> , 14, 101-111	3.9	0
4	Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-4	4.4	
3	Surrogate endpoints for new anti-cancer drugs approvals: Are we follow the right way?. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 27, 448-449	1.7	

- 2 Is there any place for novel agents in treating biliary tract cancer?. *Medical Oncology*, **2021**, 38, 19 3.7
- 1 Not only a time-saving approach: Is it the time of subcutaneous formulation for daratumumab administration?. *Journal of Oncology Pharmacy Practice*, **2021**, 27, 1751-1752 1.7